We also noticed that 58.5% of the participants did not previously experience COVID-19-like symptoms, despite being seropositive for anti-SARS-CoV-2 IgM and IgG at 49.1% and 25.6% rates, respectively, with higher IgM/IgG seroprevalence among males. This evidence concerns the gene CD40LG and COVID-19.